Edgewise Therapeutics, Inc. (EWTX) Tops Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. ABBV
5. AAPL
6. MRVL
7. CL
8. TFII
9. ORCL
10. LYB

Go back to Edgewise Therapeutics, Inc. (EWTX) Tops Q2 EPS by 8c

Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX)

August 7, 2025 10:44 AM EDT

Raymond James analyst Martin Auster reiterated a Strong Buy rating and $46.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).

The analyst comments "EWTX reported 2Q financial results and provided a corporate update. Timing for key catalysts remains on track. We continue to believe that EWTX offers among the most attractive risk/reward skews in our coverage universe into CIRRUS-HCM Part D results (beginning in 4Q25); we reiterate our Strong Buy rating. Update from EDG-7500 Phase 2 CIRRUS-HCM Part D (12-week) expected in 4Q25. EWTX previously reported 4-week Phase 2 CIRRUS-HCM (Parts B/C) data in... More